Shire (SHP) Rating Reiterated by Deutsche Bank

Shire (LON:SHP)‘s stock had its “buy” rating reissued by analysts at Deutsche Bank in a research note issued to investors on Friday.

A number of other research firms have also commented on SHP. Credit Suisse Group reaffirmed an “outperform” rating on shares of Shire in a research note on Thursday. Barclays reaffirmed an “equal weight” rating on shares of Shire in a research note on Monday, September 24th. UBS Group reaffirmed a “neutral” rating on shares of Shire in a research note on Friday, October 26th. Liberum Capital reaffirmed a “hold” rating on shares of Shire in a research note on Tuesday, July 10th. Finally, Berenberg Bank lowered Shire to a “hold” rating and lifted their price objective for the stock from GBX 4,500 ($58.80) to GBX 5,000 ($65.33) in a research note on Thursday, September 6th. Seven research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. Shire currently has an average rating of “Buy” and an average price target of GBX 4,725.30 ($61.74).

Shire stock opened at GBX 4,602.02 ($60.13) on Friday. Shire has a one year low of GBX 2,940.50 ($38.42) and a one year high of GBX 5,021 ($65.61).

Shire Company Profile

Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.

Recommended Story: How does inflation affect different investments?

Analyst Recommendations for Shire (LON:SHP)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply